Ethos Technologies Inc. Class A Common Stock (LIFE) FDA Approvals

$31.27 -0.86 (-2.68%)
As of 03:34 PM Eastern

Upcoming FDA Events for Ethos Technologies Inc. Class A Common Stock

Ethos Technologies Inc. Class A Common Stock (LIFE) has upcoming FDA regulatory milestones for Efzofitimod. The table below outlines estimated target dates and event types for these pending regulatory actions.

DrugTarget DateAnnouncement
EfzofitimodQ4 2026Provided Update
aTyr Pharma, Inc. announced that the Company expects to initiate study-related activities in the fourth quarter of 2026. (September 24, 2026)

Ethos Technologies Inc. Class A Common Stock's Drugs in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Ethos Technologies Inc. Class A Common Stock (LIFE). Over the past two years, Ethos Technologies Inc. Class A Common Stock has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as ATYR2810, ATYR0101, and Efzofitimod. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Select a button below to view the list of FDA events for that drug.

ATYR2810 FDA Regulatory Events

ATYR2810 is a drug developed by Ethos Technologies Inc. Class A Common Stock for the following indication: Non-small cell lung cancer tumor. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

ATYR0101 FDA Regulatory Events

ATYR0101 is a drug developed by Ethos Technologies Inc. Class A Common Stock for the following indication: For the treatment of interstitial lung disease. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Efzofitimod FDA Regulatory Timeline and Events

Efzofitimod is a drug developed by Ethos Technologies Inc. Class A Common Stock for the following indication: Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Ethos Technologies Inc. Class A Common Stock FDA Events - Frequently Asked Questions

In the past two years, Ethos Technologies Inc. Class A Common Stock (LIFE) has not received FDA approval for any therapies. However, the company does have drugs under review or in active clinical development.

In the past two years, Ethos Technologies Inc. Class A Common Stock (LIFE) has reported FDA regulatory activity for the following drugs: Efzofitimod, ATYR2810 and ATYR0101.

The most recent FDA-related event for Ethos Technologies Inc. Class A Common Stock occurred on November 19, 2026, involving ATYR2810. The update was categorized as "Poster Presentation," with the company reporting: "aTyr Pharma, Inc. announced a poster presentation featuring preclinical data for ATYR2810, a monoclonal antibody targeting neuropilin-2 (NRP2), at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, which is being held November 18 – 21, 2026, in Seoul, South Korea."

Current therapies from Ethos Technologies Inc. Class A Common Stock in review with the FDA target conditions such as:

  • Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) - Efzofitimod
  • Non-small cell lung cancer tumor - ATYR2810
  • For the treatment of interstitial lung disease - ATYR0101
  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NASDAQ:LIFE last updated on 11/19/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners